Cargando…
ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380449/ https://www.ncbi.nlm.nih.gov/pubmed/35983110 http://dx.doi.org/10.4103/iju.iju_81_22 |
| _version_ | 1784768886527229952 |
|---|---|
| author | Kumar, Naveen |
| author_facet | Kumar, Naveen |
| author_sort | Kumar, Naveen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9380449 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Wolters Kluwer - Medknow |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93804492022-08-17 ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer? Kumar, Naveen Indian J Urol Uroscan Wolters Kluwer - Medknow 2022 2022-07-01 /pmc/articles/PMC9380449/ /pubmed/35983110 http://dx.doi.org/10.4103/iju.iju_81_22 Text en Copyright: © 2022 Indian Journal of Urology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
| spellingShingle | Uroscan Kumar, Naveen ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer? |
| title | ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer? |
| title_full | ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer? |
| title_fullStr | ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer? |
| title_full_unstemmed | ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer? |
| title_short | ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer? |
| title_sort | arasens trial: should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer? |
| topic | Uroscan |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380449/ https://www.ncbi.nlm.nih.gov/pubmed/35983110 http://dx.doi.org/10.4103/iju.iju_81_22 |
| work_keys_str_mv | AT kumarnaveen arasenstrialshoulddarolutamidenowbeaddedtoandrogendeprivationtherapyanddocetaxelinpatientswithmetastatichormonesensitiveprostatecancer |